Roth Capital set a $45.00 target price on Nektar Therapeutics (NASDAQ:NKTR) in a research note published on Monday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other research analysts have also weighed in on NKTR. William Blair reiterated an outperform rating on shares of Nektar Therapeutics in a research note on Tuesday, July 18th. Jefferies Group LLC reiterated a buy rating and issued a $23.00 price objective on shares of Nektar Therapeutics in a research note on Friday, July 21st. Zacks Investment Research upgraded shares of Nektar Therapeutics from a hold rating to a buy rating and set a $24.00 price objective on the stock in a research note on Tuesday, August 1st. BidaskClub lowered shares of Nektar Therapeutics from a buy rating to a hold rating in a research note on Friday, August 4th. Finally, HC Wainwright started coverage on shares of Nektar Therapeutics in a research note on Monday, August 7th. They issued a buy rating and a $31.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have issued a buy rating to the company’s stock. Nektar Therapeutics currently has a consensus rating of Buy and an average target price of $32.91.

Nektar Therapeutics (NASDAQ NKTR) traded up $4.60 during trading on Monday, reaching $37.10. 17,410,800 shares of the company’s stock traded hands, compared to its average volume of 1,580,732. The company has a current ratio of 4.14, a quick ratio of 3.99 and a debt-to-equity ratio of 2.91. Nektar Therapeutics has a 1 year low of $11.41 and a 1 year high of $41.34.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported $0.37 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.21 by $0.16. The firm had revenue of $152.90 million for the quarter, compared to analyst estimates of $126.50 million. Nektar Therapeutics had a negative net margin of 42.08% and a negative return on equity of 190.68%. The company’s revenue for the quarter was up 321.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.32) EPS. equities research analysts forecast that Nektar Therapeutics will post -0.78 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Nektar Therapeutics (NKTR) Given a $45.00 Price Target at Roth Capital” was first posted by Watch List News and is owned by of Watch List News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/nektar-therapeutics-nktr-given-a-45-00-price-target-at-roth-capital/1703188.html.

In related news, SVP Maninder Hora sold 5,117 shares of the company’s stock in a transaction on Monday, November 6th. The shares were sold at an average price of $25.07, for a total transaction of $128,283.19. Following the completion of the sale, the senior vice president now directly owns 52,016 shares of the company’s stock, valued at approximately $1,304,041.12. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Howard W. Robin sold 91,714 shares of the company’s stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $19.26, for a total transaction of $1,766,411.64. Following the sale, the chief executive officer now directly owns 152,504 shares of the company’s stock, valued at $2,937,227.04. The disclosure for this sale can be found here. Insiders sold 1,024,757 shares of company stock valued at $25,974,361 over the last three months. Insiders own 5.44% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of NKTR. Janus Henderson Group PLC bought a new stake in shares of Nektar Therapeutics during the 2nd quarter worth $34,661,000. PointState Capital LP boosted its holdings in shares of Nektar Therapeutics by 281.7% during the 2nd quarter. PointState Capital LP now owns 1,731,000 shares of the biopharmaceutical company’s stock worth $33,841,000 after buying an additional 1,277,500 shares during the period. State Street Corp boosted its holdings in shares of Nektar Therapeutics by 11.3% during the 2nd quarter. State Street Corp now owns 4,408,270 shares of the biopharmaceutical company’s stock worth $86,179,000 after buying an additional 447,023 shares during the period. Numeric Investors LLC boosted its holdings in shares of Nektar Therapeutics by 2,111.5% during the 2nd quarter. Numeric Investors LLC now owns 440,729 shares of the biopharmaceutical company’s stock worth $8,616,000 after buying an additional 420,800 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in shares of Nektar Therapeutics by 3.0% during the 2nd quarter. Vanguard Group Inc. now owns 14,009,894 shares of the biopharmaceutical company’s stock worth $273,893,000 after buying an additional 401,914 shares during the period. 94.97% of the stock is owned by institutional investors and hedge funds.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.